None listed
Conditions
Interventions
None listed
Sponsors
Emami Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subjects with cuts, scratches on skin and dryness of skin 2. Willing to comply with all requirements of the study
Exclusion criteria
Exclusion criteria: 1.Subjects with a known current history of chronic skin diseases or autoimmune diseases, such as atopic dermatitis, psoriasis, chronic urticaria, vitiligo and rosacea 2. Subjects with a tattoo, a scar, moles, too many hairs or anything on the Right leg which might interfere with the evaluation. 3. Subjects with intensive exposure to sunlight or UV-rays within the previous month and foreseen during the study. 4. Subjects who have used facial blemish-lightening products, topical or oral whitening drugs. Moisturizing cream, lotion or oil within 21 days before entering the trial 5. Subjects on any other investigational products within 1 month prior to randomization 6. Subjects with known current tuberculosis, HIV, ischemic heart disease, cancer, kidney failure, liver failure 7. Pregnant and lactating women 8. Known hypersensitivity to any of the ingredients of Emami Antiseptic Cream 9. Other conditions, which in the opinion of the investigators, make patient unsuitable for enrolment or could interfere with his/her participation in, and completion of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Change in healing of minor cuts, wounds, scratches, chapped skin, lips, and cracked heels 2. Number of days require for healing of minor cuts, wounds, scratches, chapped skin, lips, and cracked heels Timepoint: Baseline visit (day 0), day 15 and end of study visit (Day 30) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in skin cutaneous moisturization 2. Change in overall skin texture/roughness (Tactile) and (Visual) 3. Change in overall skin desquamation 4. Change in softness in chapped skin and lips 5. Change in skin softness and glow 6. Skin patch test using Dermal Response Score. 7. Global assessment for overall change 8. Adverse events/adverse drug reactions including vitals. Timepoint: Baseline visit (day 0), day 15 and end of study visit (Day 30) | — |
Countries
India
Contacts
Public ContactDr Sanjay Tamoli
Target Institute of Medical Education and Research Pvt. Ltd
Outcome results
None listed